Differentiation between myopericarditis and acute myocardial infarction on presentation in the emergency department using the admission C-reactive protein to troponin ratio.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 22 12 2020
accepted: 24 02 2021
entrez: 22 4 2021
pubmed: 23 4 2021
medline: 16 9 2021
Statut: epublish

Résumé

The treatment of myopericarditis is different than that of acute myocardial infarction (AMI). However, since their clinical presentation is frequently similar it may be difficult to distinguish between these entities despite a disparate underlying pathogenesis. Myopericarditis is primarily an inflammatory disease associated with high C-reactive protein (CRP) and relatively low elevated troponin concentrations, while AMI is characterized by the opposite. We hypothesized that evaluation of the CRP/troponin ratio on presentation to the emergency department could improve the differentiation between these two related clinical entities whose therapy is different. Such differentiation should facilitate triage to appropriate and expeditious therapy. We evaluated the CRP/troponin ratio on presentation among patients consecutively included in a large single center registry that included 1898 consecutive patients comprising 1025 ST-elevation myocardial infarction (STEMI) patients, 518 Non-STEMI (NSTEMI) patients, and 355 patients diagnosed on discharge as myopericarditis. CRP and troponin were sampled on admission in all patients and their ratio was assessed against discharge diagnosis. ROC analysis of the CRP/troponin ratios evaluated the diagnostic accuracy of myopericarditis against all AMI, STEMI, and NSTEMI patients. Median admission CRP/troponin ratios were 84, 65, and 436 mg×ml/liter×ng in STEMI, NSTEMI and myopericarditis groups, respectively (p<0.001) demonstrating good differentiating capability. The Receiver-operator-curve of admission CRP/troponin ratio for diagnosis of myopericarditis against all AMI, STEMI, and NSTEMI patients yielded an area-under-the curve of 0.74, 0.73, and 0.765, respectively. CRP/troponin ratio>500 resulted in specificity exceeding 85%, and for a ratio>1000, specificity>92%. The CRP/troponin ratio can serve as an effective tool to differentiate between myopericarditis and AMI. In the appropriate clinical context, the CRP/troponin ratio may preclude further evaluation.

Sections du résumé

BACKGROUND
The treatment of myopericarditis is different than that of acute myocardial infarction (AMI). However, since their clinical presentation is frequently similar it may be difficult to distinguish between these entities despite a disparate underlying pathogenesis. Myopericarditis is primarily an inflammatory disease associated with high C-reactive protein (CRP) and relatively low elevated troponin concentrations, while AMI is characterized by the opposite. We hypothesized that evaluation of the CRP/troponin ratio on presentation to the emergency department could improve the differentiation between these two related clinical entities whose therapy is different. Such differentiation should facilitate triage to appropriate and expeditious therapy.
METHODS
We evaluated the CRP/troponin ratio on presentation among patients consecutively included in a large single center registry that included 1898 consecutive patients comprising 1025 ST-elevation myocardial infarction (STEMI) patients, 518 Non-STEMI (NSTEMI) patients, and 355 patients diagnosed on discharge as myopericarditis. CRP and troponin were sampled on admission in all patients and their ratio was assessed against discharge diagnosis. ROC analysis of the CRP/troponin ratios evaluated the diagnostic accuracy of myopericarditis against all AMI, STEMI, and NSTEMI patients.
RESULTS
Median admission CRP/troponin ratios were 84, 65, and 436 mg×ml/liter×ng in STEMI, NSTEMI and myopericarditis groups, respectively (p<0.001) demonstrating good differentiating capability. The Receiver-operator-curve of admission CRP/troponin ratio for diagnosis of myopericarditis against all AMI, STEMI, and NSTEMI patients yielded an area-under-the curve of 0.74, 0.73, and 0.765, respectively. CRP/troponin ratio>500 resulted in specificity exceeding 85%, and for a ratio>1000, specificity>92%.
CONCLUSION
The CRP/troponin ratio can serve as an effective tool to differentiate between myopericarditis and AMI. In the appropriate clinical context, the CRP/troponin ratio may preclude further evaluation.

Identifiants

pubmed: 33886564
doi: 10.1371/journal.pone.0248365
pii: PONE-D-20-40200
pmc: PMC8062049
doi:

Substances chimiques

Troponin 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0248365

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Int J Cardiol. 2008 Jun 23;127(1):17-26
pubmed: 18221804
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
JAMA. 2003 Jul 16;290(3):353-9
pubmed: 12865376
Circulation. 2011 Mar 15;123(10):1092-7
pubmed: 21357824
Singapore Med J. 2015 Jan;56(1):e1-3
pubmed: 25640104
AJR Am J Roentgenol. 2009 Jan;192(1):254-8
pubmed: 19098207
J Clin Invest. 2003 Jun;111(12):1805-12
pubmed: 12813013
Eur Heart J. 2020 Oct 1;41(37):3495-3497
pubmed: 33085966
J Am Heart Assoc. 2016 May 20;5(5):
pubmed: 27207959
Cardiovasc Ultrasound. 2012 Nov 05;10:42
pubmed: 23121688
J Am Coll Cardiol. 2003 Mar 19;41(6):916-24
pubmed: 12651034

Auteurs

Simcha R Meisel (SR)

Heart Institute, Hillel Yaffe Medical Center, Hadera, Israel.

Hamuda Nashed (H)

Heart Institute, Hillel Yaffe Medical Center, Hadera, Israel.

Randa Natour (R)

Heart Institute, Hillel Yaffe Medical Center, Hadera, Israel.

Rami Abu Fanne (R)

Heart Institute, Hillel Yaffe Medical Center, Hadera, Israel.

Majdi Saada (M)

Heart Institute, Hillel Yaffe Medical Center, Hadera, Israel.

Naama Amsalem (N)

Heart Institute, Hillel Yaffe Medical Center, Hadera, Israel.

Carmel Levin (C)

Heart Institute, Hillel Yaffe Medical Center, Hadera, Israel.

Ofer Kobo (O)

Heart Institute, Hillel Yaffe Medical Center, Hadera, Israel.

Aaron Frimerman (A)

Heart Institute, Hillel Yaffe Medical Center, Hadera, Israel.

Yaniv Levi (Y)

Heart Institute, Hillel Yaffe Medical Center, Hadera, Israel.

Jameel Mohsen (J)

Heart Institute, Hillel Yaffe Medical Center, Hadera, Israel.

Avraham Shotan (A)

Heart Institute, Hillel Yaffe Medical Center, Hadera, Israel.

Ariel Roguin (A)

Heart Institute, Hillel Yaffe Medical Center, Hadera, Israel.

Michael Kleiner-Shochat (M)

Heart Institute, Hillel Yaffe Medical Center, Hadera, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH